Envista Holdings Co. (NYSE:NVST) Receives Average Recommendation of “Hold” from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have earned a consensus rating of “Hold” from the sixteen analysts that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $20.65.

NVST has been the subject of a number of research reports. Robert W. Baird lifted their target price on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Mizuho began coverage on shares of Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective for the company. Stifel Nicolaus increased their target price on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Wells Fargo & Company assumed coverage on shares of Envista in a research report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price target for the company. Finally, Piper Sandler increased their price target on Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st.

Envista Stock Performance

NVST opened at $19.24 on Monday. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of -2.48, a PEG ratio of 2.71 and a beta of 1.31. Envista has a 12-month low of $15.15 and a 12-month high of $25.64. The business has a 50 day moving average of $20.22 and a 200-day moving average of $18.46.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.03. The company had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The company’s revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 earnings per share. On average, equities research analysts expect that Envista will post 0.72 earnings per share for the current year.

Institutional Investors Weigh In On Envista

Large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Envista during the 3rd quarter valued at $31,000. GAMMA Investing LLC lifted its position in shares of Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares in the last quarter. Huntington National Bank raised its stake in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares during the period. Blue Trust Inc. lifted its stake in Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.